PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
19.10
-0.68 (-3.44%)
At close: Apr 1, 2025, 4:00 PM
19.36
+0.26 (1.37%)
After-hours: Apr 1, 2025, 4:04 PM EDT
PureTech Health Revenue
PureTech Health had revenue of $288.00K in the half year ending June 30, 2024, a decrease of -95.90%. This brings the company's revenue in the last twelve months to $468.00K, down -96.01% year-over-year. In the year 2023, PureTech Health had annual revenue of $3.33M, down -78.68%.
Revenue (ttm)
$468.00K
Revenue Growth
-96.01%
P/S Ratio
949.15
Revenue / Employee
$5,200
Employees
90
Market Cap
444.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PRTC News
- 21 days ago - PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair - Business Wire
- 6 weeks ago - PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform - Business Wire
- 2 months ago - PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire
- 2 months ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 3 months ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire
- 3 months ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire
- 3 months ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 - Business Wire
- 4 months ago - PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting - Business Wire